3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase NA
1
Phase 2
1
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
1
NETWORK
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Breast Neoplasms
13
Carcinoma, Non-Small-Cell Lung
11
Neoplasm Metastasis
7
Brain Neoplasms
7
Rectal Neoplasms
6
Lung Neoplasms
6
Stomach Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Head and Neck Neoplasms
5
Urinary Bladder Neoplasms
4
Prostatic Neoplasms
4
Esophageal Squamous Cell Carcinoma
4
Esophageal Neoplasms
4
Uterine Cervical Neoplasms
3
Pancreatic Neoplasms
3
Melanoma
3
Glioblastoma
3
Colorectal Neoplasms
3
Colonic Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Ovarian Neoplasms
2
Neoplasms
2
Mouth Neoplasms
2
Laryngeal Neoplasms
2
Inflammatory Breast Neoplasms
2
Glioma
2
Central Nervous System Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Adenocarcinoma
2
Vaginal Neoplasms
1
Interventions
Oxaliplatin
10
Fluorouracil
7
Leucovorin
6
Gemcitabine
6
Docetaxel
6
Capecitabine
6
Paclitaxel
5
Cisplatin
5
zolbetuximab
4
Ramucirumab
3
Pemetrexed
3
Drug Therapy
3
Carboplatin
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
regorafenib
2
pembrolizumab
2
Vinorelbine
2
Surgical Procedures, Operative
2
Radiotherapy
2
Nivolumab
2
Neoadjuvant Therapy
2
Cyclophosphamide
2
Chemoradiotherapy
2
Bevacizumab
2
Afatinib
2
vandetanib
1
trifluridine tipiracil drug combination
1
trastuzumab deruxtecan
1
tislelizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Adenocarcinoma
×
Surgical Procedures, Operative
×
Clear all
NCT01419002
2015-07-29
Net-Pac
CHIR-Net
Phase 3
Terminated
5 enrolled
NCT01521702
2015-03-20
NEOPAC
Institut Paoli-Calmettes
Phase 3
Completed
2 enrolled